Top Study on Bladder Cancer Industry Report 2017

1
Opportunity Analyzer Bladder Cancer
Opportunity Analysis and Forecasts to
2017byGlobalData

• Explore all reports for Pharmaceuticals market
  _at_ http//www.rnrmarketresearch.com/reports/life-sc
  iences/pharmaceuticals .

2
Opportunity Analyzer Bladder Cancer
Opportunity Analysis and Forecasts to 2017

• Bladder cancer is a urologic malignancy arising
  from the epithelial lining of the urinary
  bladder. Although it is the ninth most common
  cancer worldwide in men and women, with the
  highest recurrence rate of any malignancy,
  relatively little is known about its etiology.
  There has been little development over the past
  20 years in bladder cancer, with a huge void of
  unmet met needs which are yet to be filled.
• The disease can be spilt into three main
  categories NMIBC (non-muscle invasive bladder
  cancer), muscle invasive disease and metastatic
  disease. The standards of care within all of
  these settings are generics BCG immunotherapy/
  mitomycin c (NMIBC) and the off label use of
  GemCis (muscle invasive disease and metastatic
  disease).
• Progression and recurrence rates are relative to
  clinical stage, but are generally high,
  especially for patients with the aggressive
  carcinoma in situ (CIS) classification. This is
  one patient subgroup which has particularly high
  unmet needs.
• There are clear unmet needs for higher
  efficacious drugs that can reduce progression and
  recurrence rates as well as cure the disease,
  surprisingly big pharma seems to have taken a
  back seat in development, instead collaborating
  with independent researchers to head trials with
  their already marketed drugs. Most of the current
  pipeline is being investigated by small-medium
  sized biotechs.

Inquire for a discount on this report _at_
http//www.rnrmarketresearch.com/contacts/discount
?rname141229 .
3
Opportunity Analyzer Bladder Cancer
Opportunity Analysis and Forecasts to 2017

• Key Questions Answered
• Which bladder cancer patient segments have the
  greatest unmet needs?
• What are the RD strategies companies are
  pursuing in the bladder cancer space?
• Why has there been a void of interest from big
  pharma in this highly underserved market?
• What are the most promising pipeline agents for
  bladder cancer?
• How do their clinical and commercial attributes
  compare to one another?
• What opportunities will remain for future players
  following the launch of these pipeline agents?
• What is the potential for predictive biomarkers
  and targeted therapies in the bladder cancer
  setting?
• Key Findings
• GlobalData forecasts the bladder cancer market in
  the 6MM to grow modestly from 239.3m in 2012 to
  297.5m in 2017, at a CAGR of 4. The main driver
  of growth in the global bladder cancer market
  will be the increase in number of incident cases
  across the study period in the 6MM and the
  entrance of EOquin into the market towards the
  end of the forecast period.
• Although the level of unmet need in the bladder
  cancer market is high, KOLs are generally not
  impressed by any of the pipeline products and
  they do not expect any of them to drastically
  change the treatment landscape. The unmet needs
  will hence remain after the forecast period in
  turn rendering the bladder cancer market as
  highly lucrative and commercially viable for
  developers.

Complete report available at _at_ http//www.rnrmarke
tresearch.com/opportunityanalyzer-bladder-cancer-o
pportunity-analysis-and-forecasts-to-2017-market-r
eport.html .
4
Opportunity Analyzer Bladder Cancer
Opportunity Analysis and Forecasts to 2017

• Scope
• Overview of bladder cancer, including
  epidemiology, etiology, pathophysiology,
  symptoms, diagnosis, and disease management.
• Topline bladder cancer therapeutics market
  revenue from 2012-2017. Annual cost of therapy,
  and major marketed and pipeline drug sales in
  this forecast period are included.
• Key topics covered include strategic competitor
  assessment, market characterization, unmet needs,
  RD strategies, and clinical trial design for the
  bladder cancer therapeutics market.
• Pipeline analysis comprehensive data split
  across different phases, emerging novel trends
  under development, synopses of innovative
  early-stage projects, and detailed analysis of
  late-stage pipeline drugs. An interactive
  clinical and commercial analyzer tool is
  available.
• Analysis of the current and future market
  competition in the global bladder cancer market.
  Insightful review of the key industry drivers,
  restraints and challenges. Each trend is
  independently researched to provide qualitative
  analysis of its implications.
• Reasons to buy
• Develop and design your in-licensing and
  out-licensing strategies through a review of
  pipeline products and technologies, and by
  identifying the companies with the most robust
  pipeline.
• Develop business strategies by understanding the
  trends shaping and driving the global bladder
  cancer market.

Download sample of this report at _at_
http//www.rnrmarketresearch.com/contacts/request-
sample?rname141229 .